APPENDIX

Ash1 counteracts Polycomb repression independent of H3K36 methylation.

Eshagh Dorafshan¹, Tatyana G. Kahn¹, Alexander Glotov¹, Mikhail Savitsky¹, Matthias Walther^{2,3}, Gunter Reuter² and Yuri B. Schwartz^{1, #}

¹ Department of Molecular Biology, Umeå University, Umeå, Sweden.

² Institute of Developmental Genetics, Martin-Luther University of Halle-Wittenberg, Halle, Germany.


³ Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.

[#]correspondence should be addressed to: <u>yuri.schwartz@umu.se</u>

Table of contents


Appendix Figure S1	 2
Appendix Figure S2	 3
Appendix Figure S3	 5
Appendix Figure S4	 7
Appendix Figure S5	 9
Appendix Figure S6	 10
Appendix Figure S7	 12
Appendix Figure S8	 15
Appendix Figure S9	 17
Appendix Figure S10	 18
Appendix Figure S11	 19
Appendix Figure S12	 21
Appendix Table S1	 23
Appendix Table S2	 26
Appendix Table S3	 27

Set2¹



Appendix Figure S1. Adult phenotype of the *Set2* loss of function mutant. Most flies homozygous for the *Set2*¹ null allele die at the late larval or early pupal stages. Out of 221 homozygous *Set2*¹ pupae, only one male fully developed to pharate adult stage. In that animal, shown here, no homeotic transformations are visible. The halters (h), third legs and all tergites (t1-t6) appear normal and show no signs of posterior to anterior transformations.

Α




Appendix Figure S2. Complementation of *ash1* mutations by transgenic Ash1 variants. (A) Schematics of crosses and the progeny classes. To test whether different variants of the transgenic Ash1 can compensate for the *ash1* loss of function, the transgenes were introduced into the flies trans-heterozygous for $ash1^{22}$ and $ash1^{9011}$ alleles. To this effect, females of a

strain containing one copy of the Ash1 transgene, balanced over CyO on the second chromosome, and the ash1²² allele, balanced over TM3, Ser, Act-GFP on the third chromosome, were crossed to males from a strain containing the same second chromosome combination but $ash1^{9011}$ instead of $ash1^{22}$ on the third chromosome (Forward cross). The reciprocal cross was also set up, where the genotypes of males and females were switched (Reverse cross). Three different Ash1 transgenes were used in this experiment. One (Ash1FL) contained the full-length ash1 Open Reading Frame (ORF), and the two truncated variants contained ORFs that lacked either the SET domain (Ash1 ASET) or the PHD domain (Ash1 APHD). The expression of all transgenes was driven by the *Ubiquitin* (*Ubi-p63E*) promoter. In the progeny, Class I (yellow rectangle) and Class II (grey rectangle) contained two copies of the Ash1 transgenes. (B-C) The viability of $ash1^{22}/ash1^{9011}$ flies complemented by different transgenic Ash1 variants. The ratio between Class I/Class II progeny was calculated for each transgenic Ash1 variant to gauge the viability (rescue). In the case of complete rescue, the Class I/Class II ratio is expected to be $\frac{1}{2}$, which we designated as 100%. The χ^2 test shows that the two copies of Ash1 Δ SET, Ash1 Δ PHD and Ash1FL transgenes restore the viability of $ash1^{22}/ash1^{9011}$ flies to comparable extent. Graph (B) corresponds to the Forward cross in (A) and graph (C) corresponds to the Reverse cross. n indicates the number of Class I + Class II progeny counted.

Α Step 1 $\mathbb{Q}\frac{\textit{Elav-Gal4}, \Delta \textit{HisC}}{\textit{CyO}}; \frac{\textit{VK33}\textit{\{H3K36Rx12\}}}{\textit{TM6}, \textit{Tb}} \times \textit{O}^{\intercal} \frac{+}{+}; \frac{\textit{ash1}^{22}}{\textit{TM3}, \textit{Ser}, \textit{Act-GFP}}$ Step 2 Step 3 $\mathbb{P}\frac{lf}{CyO}; \frac{VK33\{H3K36Rx12\}, ash1^{22}}{TM6, Tb} \times \mathcal{O}^{+}_{+}; \frac{ash1^{9011}}{TM3, Ser.Act-GFP}$ Step 4 a) $\varphi \frac{+}{lf}$; $\frac{VK33\{H3K36Rx12\},ash1^{22}}{TM3,Ser,Act-GFP} \times \circ \frac{+}{Cyo}$; $\frac{ash1^{9011}}{TM6,Tb}$ b) $\varphi \frac{Elav-Gal4, \Delta HisC}{CyO}$; $\frac{VK33\{H3K36Rx12\}}{TM6,Tb} \times \circ \frac{-lf}{CyO}$; $\frac{MKRS}{TM6,Tb}$ Step 5 $\mathbb{P}\frac{lf}{CyO}; \frac{VK33\{H3K36Rx12\}, ash1^{22}}{TM6, Tb} \times \overset{\bullet}{\longrightarrow} \frac{Elav-Gal4, \Delta HisC}{CyO}; \frac{MKRS}{TM6, Tb}$ Step 6 $\frac{\textit{Elav-Gal4}, \Delta \textit{HisC}}{\textit{CyO}}; \frac{\textit{VK33}\textit{H3K36Rx12}\textit{,} \textit{ash1}^{22}}{\textit{TM6}, \textit{Tb}}$ В Step 1 $\begin{array}{c} \mathbb{Q} \quad \frac{lf}{CyO}; \frac{MKRS}{TM6, Tb} \hspace{0.1 cm} \bigstar \hspace{0.1 cm} \bigcirc^{\bullet} \hspace{0.1 cm} \frac{UAS-2xYFP, \triangle HisC}{CyO, Ftz, lacZ}; \hspace{0.1 cm} \stackrel{+}{+} \end{array}$ Step 2 a) $Q \frac{UAS-2xYFP, \Delta HisC}{CyO}$; $\frac{+}{TM6, Tb} \times O^* \frac{UAS-2xYFP, \Delta HisC}{CyO}$; $\frac{+}{MKRS}$ b) $Q \frac{+}{CyO}$; $\frac{ash1^{9011}}{TM6, Tb} \times O^* \frac{+}{If}$; $\frac{ash1^{9011}}{TM6, Tb}$ Step 3 $\mathbb{Q} \frac{UAS-2xYFP, \Delta HisC}{CyO}; \frac{MKRS}{TM6, Tb} \times \stackrel{\text{of}}{\longrightarrow} \frac{If}{CyO}; \frac{ash1^{9011}}{TM6, Tb}$ Step 4 $\frac{\text{UAS-2xYFP}, \Delta \text{HisC}}{\text{CvO}}, \frac{\text{ash1}^{9011}}{\text{TM6, Tb}}$

Appendix Figure S3. Generation of fly strains that combine the *Elav-Gal4*, Δ *HisC or UAS-*2xYFP, Δ *HisC*, chromosomes with *ash1* mutations and the VK33{H3K36Rx12} transgene. (A) To combine the *Elav-Gal4*, Δ *HisC* chromosome with the *ash1*²² allele and the VK33{H3K36Rx12} transgene, the female flies with the *Elav-Gal4*, Δ *HisC/CyO* 2nd chromosomes, and the VK33{H3K36Rx12} transgene on the third chromosome, were crossed with the *ash1*²²/TM3, *Ser*, *Act-GFP* males (Step 1). From the progeny of Step 1, females lacking the TM3, *Ser*, *Act-GFP* balancer but containing the *CyO* balancer were crossed to males of the double-balancer strain (*If/CyO*; *MKRS/TM6*, *Tb*) (Step 2). The recombination between *ash1*²²

and VK33{H3K36Rx12} occurred in females in this step. Individual If/CyO females with the TM6, Tb balancer chromosome, from the progeny of Step 2, were crossed to the ash19011/TM3,Ser,Act-GFP males (Step 3). Allowing the females to lay eggs, the genomic DNA of these females was extracted and screened by PCR for the presence of the $ashl^{22}$ mutation and the VK33{H3K36Rx12} transgene (see Appendix Figure S5). From the progeny of the Step 3 crosses, the females that contained the recombinant $VK33{H3K36Rx12},ash1^{22}$ chromosome, the If marker and the TM3, Ser, Act-GFP balancer were crossed to males that carried the CyO and TM6, Tb balancers (Step 4a). In parallel (Step 4b), the females from the Elav-Gal4, AHisC/CyO; VK33 {H3K36Rx12}/TM6b, Tb strain were crossed to males of the double-balancer strain. From the progeny of Step 4a, the If/CyO females with the TM6,Tb balancer were crossed with the CyO males carrying both the MKRS marker and the TM6, Tb balancer but lacking the If marker (Step 5). In Step 6, the females and males carrying the CyO and TM6, Tb balancer chromosomes but lacking the If and MKRS markers were selected to establish the Elav-Gal4, AHisC/CyO; VK33{H3K36Rx12}, ash1²²/TM6, Tb fly stock. (B) To combine the UAS-2xYFP, $\Delta HisC$ chromosome with the $ash1^{9011}$ allele, females of the doublebalancer line were crossed with the UAS-2xYFP, AHisC/CyO males (Step 1). In Step 2, the females carrying CyO and TM6, Tb balancers and lacking the If and MKRS markers were crossed with the CyO males lacking the If marker and carrying the MKRS chromosome (Step 2a). In parallel (Step 2b), the CyO females and the If males, both carrying TM6, Tb balancer, and both from the progeny of Step 3 in (A), were crossed to each other. In Step 3, females with the MKRS chromosome and the TM6, Tb balancer from the progeny of Step 2a were crossed to the *If/CyO* males carrying *TM6*, *Tb* balancer, from the progeny of Step 2b. In the next step the flies with the CyO and TM6, Tb balancers but lacking If and MKRS were selected from the progeny of Step 3 to establish the strain with the genotype shown in Step 4.



В


	YFP positive (0	Class I)	YFP negative (Class III)		
Starting number of flies	500		650		
Number of dead pupae	Class la (non-Tb)	2	0		
Number of dead pupae	Class lb (Tm6,Tb)	186 (37%)			
Number of flies hatched	0		Class Illa (non-Tb)	0	
Number of mes natched	0		Class IIIb (Tm6,Tb)	403 (62%)	

Appendix Figure S4. Genetic interaction between the *ash1* and *H3K36R* mutations. (A) To generate the $\Delta HisC;ash1^-,H3K36R$ animals, the *Elav-Gal4*, $\Delta HisC$ /*CyO*; *VK33{H3K36Rx12}, ash1²² /TM6,Tb* flies from Appendix Figure S3A were crossed with the *UAS-2xYFP,* Δ *HisC/CyO; ash1*⁹⁰¹¹/*TM6*,*Tb* flies from Appendix Figure S3B. In the progeny, three classes are expected. Classes I and II both show the YFP signal in the fluorescent stereomicroscope and therefore are distinguishable from Class III which lacks the YFP signal. Although both Classes I and II show the YFP signal, the Class II progeny die at early embryonic stage due to the lack of zygotic histone supply. The *Tb* marker on the *TM6*,*Tb* chromosome is used to distinguish the Class Ib flies from Class Ia and Class IIIb flies from Class IIIa. (**B**) Analysis of Class I and Class III (control) viability. While no adult flies emerge from the Class I larvae, 62% (close to expected) of the Class III (shown as class IIIb) larvae develop to the adult fly stage. Note that Class IIIa larvae are expected to die since they carry both the *ash1*²² and *ash1*⁹⁰¹¹ alleles.

5: ash1²²/TM3,Ser,ActGFP 1: VK33{H3K36Rx12},ash1²² fly #1 2: VK33{H3K36Rx12}.ash1²² fly #2 6: Elav-Gal4,∆HisC / CyO ; VK33{H3K36Rx12}/TM6,Tb 2: VK33{H3K36Rx12},ash1 TIY#2 3: VK33{H3K36Rx12},ash1²² fly#3 4: VK33{H3K36Rx12},ash1²² fly#4 7: wild-type (Oregon R) 8: No Template Control ash1²² amplicon H3K36R amplicon 300 bp 250 bp 6 1 2 3 4 5 7 8 2 3 4 5 6 1


Amplicons	Forward primer	Reverse primer	Product in mutant/transgenic line	Product in wild-type
ash1 ²²	ash1-22.2	ash1-21.rev	264 bp	No product
H3K36R	H3K36R	His3-rev	300 bp	No product

Appendix Figure S5. The screen for the recombination between $ash1^{22}$ and the H3K36R transgene. The single flies, described in Appendix Figure S3A, were genotyped by PCR, using the primer specific for the $ash1^{22}$ mutation and the $VK33\{H3K36Rx12\}$ transgene. The forward primer in the $ash1^{22}$ amplicon is designed to match the single nucleotide substitution in the $ash1^{22}$ mutation and therefore anneals only to the mutant but not to the wild-type genomic DNA. In the H3K36R amplicon, one of the primers (H3K36R) uses the three nucleotide-difference between the wild-type and the transgenic copies of the His3.2 gene and therefore is specific for the $VK33\{H3K36Rx12\}$ transgene as the template for PCR reaction. Four single flies positive for both the $ash1^{22}$ mutation and the $VK33\{H3K36Rx12\}$ transgene are shown here. PCR products were analyzed by the electrophoresis in 2% agarose gel. M = 50bp DNA Ladder.



Appendix Figure S6. Generation of the Drosophila strain that combines the His3.3 deletions and the UAS-2xYFP, $\Delta HisC$ chromosome. To generate the w, $\Delta H3.3B(w^+)$, hsp-Flp ; Df(2L)His3.3A, ElavGal4, $\Delta HisC/CyO$; +/+ fly strain, the FM7i, ActGFP chromosome was first introduced into the UAS-2xYFP, $\Delta HisC/CyO$; +/+ fly strain (Step 1). In the progeny of Step 1, the females with FM7i,ActGFP balancer and without the second chromosome marked by Sco (therefore carrying the UAS-2xYFP, AHisC chromosome) were collected and crossed to males of the w, $\Delta His3.3B$ (w⁺), hsp-Flp; Df(2L)His3.3A/SM6B, Cy genotype (Step 2). In Step 3, the females with FM7i,ActGFP balancer (carrying the His3.3B deletion) and without second chromosome balancer were selected. This provides a chance for recombination between Df(2L)His3.3A and UAS-2xYFP, $\Delta HisC$. These females were crossed with the males hemizygous for FM7i,ActGFP and carrying either the SM6B,Cy or CyO,ActGFP second chromosome balancer. In Step 4, the female progeny of Step 3, carrying either SM6B, Cy or *CyO*,*ActGFP* were selected and crossed individually with the *FM7i*,*ActGFP*; nos[4L],sco[rv9R],b[1]/CyO,ActGFP males. Note that all females contained the His3.3B

deletion balanced over *FM7i*,*ActGFP*. After several days of egg deposition, genomic DNA was extracted from the single females of each cross. This DNA was used to screen for recombination on the second chromosome (simultaneous presence of the $\Delta HisC$ deletion, the *UAS-2xYFP* transgene, and the *His3.3A* deletion). Note that the *CyO*,*ActGFP* balancer will interfere with the detection of the YFP signal used to select for embryos homozygous for $\Delta HisC$ (for details see Figure EV5). To replace *CyO*,*ActGFP* with the *CyO* balancer, the female progeny of the crosses with the recombinant second chromosome (from Step 4), were crossed to the males hemizygous for the *His3.3B* deletion, carrying the *If* marker and the *CyO* balancer (Step 5). Finally, in Step 6, the female and male progeny of Step 5, lacking both the *FM7i*,*ActGFP* balancer and the *If* marker were selected to establish the strain to be used for the cross described in Figure EV5. The founders of this stock were PCR genotyped as described in Appendix Figure S9.




Appendix Figure S7. Generation of Drosophila males that combine the His3.2 and His3.3 deletions with Elav-Gal4, AHisC and the H3K36R transgene. To generate the Df(2L)His3.3A,ElavGal4, AHisC/CyO $w, \Delta H3.3B(w^+), hsp-Flp$; $VK33{H3K36Rx12}/TM6,Tb/+$ fly strain, we started by introducing the first chromosome balancer (FM7i,ActGFP) into the Elav-Gal4, AHisC/CvO; VK33 (H3K36Rx12)/TM6, Tb fly strain (Step 1). The FM7i, ActGFP balancer is marked with the dominant marker Bar. In the progeny of the Step 1 cross, we selected the male flies showing the Bar phenotype (hence FM7i,ActGFP), lacking the Sco marker on the second chromosome (therefore carrying the *Elav-Gal4* transgene) and lacking the *TM6,Tb* third balancer (thus containing *VK33*{*H3K36Rx12*}). Those males were crossed with the $w, \Delta His3.3B(w^+), hsp-Flp;$ Df(2L)His3.3A/SM6B, Cy females (Step 2). This introduces the His3.3B deletion (balanced over FM7i,ActGFP) and generates conditions to recombine the Df(2L)His3.3A deletion and the *Elav-Gal4* transgene. To allow the recombination in Step 3, the female offspring from Step 2 that lacked the second chromosome balancer was backcrossed to the same males as in Step 2. In the next step (Step 4), the female progeny from Step 3 that had been balanced over CyO,ActGFP was crossed individually to the If/CyO; ash19011/TM6,Tb males. Note that the *VK33*{*H3K36Rx12*} chromosome is homozygous lethal, probably due to additional mutation. After several days of egg deposition, genomic DNA of the single females from each individual cross was extracted and screened by PCR for the presence of the Elav-Gal4 transgene, the $\Delta HisC$ and $\Delta His3.3A$ deletions on the second chromosome and the VK33{H3K36Rx12} transgene on the third chromosome. For next step, the female and male offspring from the Step 4 individual crosses were selected to have both the His3.3A, Elav-Gal4, AHisC second chromosome balanced over CyO, and the TM6, Tb balancer. We also required that the selected flies lacked the FM7i, ActGFP balancer, which ensured the presence of the His3.3B deletion on the first chromosome. Selected females and males were crossed together (Step 5). In Step 6, the single females and males with the TM6, Tb balancer from the progeny of Step 5 were used to set up individual crosses. Following several days of egg deposition, genomic DNA was of the individual males and females from each cross was extracted and tested by PCR for the presence of the *His3.3B* deletion and the *VK33*{*H3K36Rx12*} transgene. Note that we can detect the His3.3B deletion only if homozygous. In the process, we realized that the females homozygous for the *His3.3B* deletion, heterozygous for the recombinant second chromosome and carrying the VK33{H3K36Rx12} transgene on the third chromosome are not viable. Therefore, in step 7, females, homozygous, and males, hemizygous, for the His3.3B deletion both carrying the third chromosome balancer were crossed individually. After giving time for egg deposition, DNA was extracted from the single males and females of each cross and used to genotype single flies by PCR. Females were selected for the deletion of His3.3A, His3.3B and the HisC cluster as well as the presence of the Elav-Gal4 transgene on the second chromosome. Males were additionally selected for the presence of the VK33{H3K36Rx12} transgene on the third chromosome. For details of genotyping see Appendix Figure S10. The selected males and females were used in the Step 8 cross. Unfortunately this cross did not result in a stable strain but yielded enough males with the desired genotype $(w, \Delta H3.3B(w^+), hsp-Flp$; Df(2L)His3.3A,ElavGal4, AHisC/CyO; VK33{H3K36Rx12}/TM6, Tb or +) which were used in the cross described in Figure EV5.

- 1: w,∆His3.3B (w+),hsp-Flp; Df(2L)His3.3A,Elav-Gal4,∆HisC /Df(2L)His3.3A,UAS-2xYFP,∆HisC ; VK33{H3K36Rx12} / +
- 2: w,∆His3.3B (w+),hsp-Flp ; Df(2L)His3.3A / SM6B,Cy ; +/+
- 3: yw ; Elav-Gal4,∆HisC / CyO ; TM6,Tb / VK33{H3K36Rx12}
- 4: w; UAS-2xYFP,∆HisC / CyO,Ftz,IacZ ; +/+
- 5: wild-type (Oregon R)
- 6: no-template control

Embryo

Control for deletion of *His3.3B* and *His3.3A* Positive control for Gal4 and H3K36R amplicons Control for deletion of *HisC* and presence of YFP



Amplicon	Forward primer	Reverse primer	Product in mutant/transgenic line	Product in wild-type
∆His3.3A	His3.3A_fwd	His3.3A_rev	450 bp	1054 bp
∆His3.3B	His3.3B_fwd	His3.3B_rev	No product	About 500 bp
∆HisC	HisC.2	Pry4	About 500 bp	No product
H3K36R	H3K36R	His3-rev	300 bp	No product
Gal4	osGAL4:DBD-fw	CP190-GAL4	About 500 bp	No product
YFP	eGFP F	eGFP R	About 100 bp	No product
Wild-type His3	3.2 H3WT	His3-rev	No product	300 bp

Appendix Figure S8. PCR genotyping of a Class I embryo from the cross on Figure EV5 (YFP positive, wild-type zygotic H3.2 and H3.3 histones replaced with H3R36). Shown are the results of one representative genotyping experiment. To verify the identity of the Class I embryos described in Figure EV5, the genomic DNA from a single YFP+ embryo was extracted and subjected to seven separate PCR reactions using primer pairs specific for different histone H3 deletions, the presence of the *His3.2* gene and the *Elav-Gal4, UAS-2xYFP* and *VK33*{*H3K36Rx12*} transgenes. The products of each PCR reaction were analyzed by the electrophoresis in 2% agarose gel. M = 100bp DNA Ladder.


- 1: w, Δ His3.3B (w+),hsp-Flp ; Df(2L)His3.3A,UAS-2xYFP, Δ HisC / CyO ; +/+
- 2: w, Δ His3.3B (w+),hsp-Flp ; Df(2L)His3.3A,UAS-2xYFP, Δ HisC / CyO ; +/+
- 3: w, Δ His3.3B (w+),hsp-Flp ; Df(2L)His3.3A,UAS-2xYFP, Δ HisC / CyO ; +/+
- 4: w, Δ His3.3B (w+),hsp-Flp ; Df(2L)His3.3A / SM6B,Cy ; +/+
- 5: w; UAS-2xYFP,∆HisC / CyO,Ftz,IacZ ; +/+
- 6: wild-type (Oregon R)
- 7: no-template control

Female #1

Female #2

Male #1

Control for deletion of *His3.3B* and *His3.3A* Control for deletion of *HisC* and presence of *YFP*



Amplicon	Forward primer	Reverse primer	Product in mutant/transgenic line	Product in wild-type
ΔHis3.3A	His3.3A_fwd	His3.3A_rev	450 bp	1054 bp
ΔHis3.3B	His3.3B_fwd	His3.3B_rev	No product	About 500 bp
ΔHisC	HisC.2	Pry4	About 500 bp	No product
YFP	eGFP F	eGFP R	About 100 bp	No product


Appendix Figure S9. PCR-genotyping of the parental flies for the cross of Step 6 on Appendix Figure S6. The selection of the parents (2 females and 1 male) for the correct cross described in Appendix Figure S6 (Step 6) was done by PCR. Genomic DNA was extracted from individual flies and a set of PCR reactions with specific primer pairs (described in the table below) were used detect the deletion of the histone cluster ($\Delta HisC$), the deletions of the *His3.3A* and *His3.3B* genes and the presence of the *UAS-2xYFP* transgene. Shown are the pictures of the indicated PCR products separated by the electrophoresis in 2% agarose gel. 100bp DNA Ladder marker is indicated as M.

- 1: w?, \(\Delta His3.3B (w+), hsp-Flp ; Df(2L) His3.3A, Elav-Gal4, \(\Delta HisC / CyO ; TM6, Tb / + \)
- 3: w, Δ His3.3B (w+),hsp-Flp ; Df(2L)His3.3A / SM6B,Cy ; +/+
- 4: yw ; Elav-Gal4,∆HisC / CyO ; TM6,Tb /VK33{H3K36Rx12}
- 5: wild-type (Oregon R)
- 6: no-template control H3K36R amplicon AHis3 3B amplicon 500 bp 300 bp 300 bp 2 M M 3 5 2 M М 1 6 4 5 6 Gal4 amplicon ∆HisC amplicon ∆His3.3A amplicon 1000 Бр 1000 bp 500 bp 500 bp 500 bp 2 М 4 5 6 М 3 5 6 м 2 2 М 5 6 Μ 1 1 Product in mutant/transgenic line Amplicon Forward primer Reverse primer Product in wild-type His3.3A_rev 450 bp 1054 bp About 500 bp ∆His3.3A His3.3A fwd ΔHis3.3B His3.3B fwd His3.3B rev No product HisC.2 Pry4 About 500 bp AHisC No product H3K36R His3-rev 300 bp No product About 500 bp Gal4 osGAL4:DBD-fw CP190-GAL4 No product

Appendix Figure S10. PCR-genotyping of the parental flies for the cross of Step 7 on Appendix Figure S7. The selection of the parents (1 female and 1 male) for the correct cross described in Appendix Figure S7 (Step 7) was done by PCR genotyping. Genomic DNA was extracted from individual flies and a set of PCR reactions with specific primer pairs (described in the table below) were used detect the deletion of the histone cluster (*ΔHisC*), the deletions of the *His3.3A* and *His3.3B* genes and the presence of the *Elav-Gal4* and *VK33[H3K36Rx12]* transgenes. Shown are the pictures of the indicated PCR products separated by the electrophoresis in 2% agarose gel. Lanes marked with asterisks correspond to PCR reactions with genomic DNAs of single flies with undesirable genotypes. Crosses with such parents were discarded. 100bp DNA Ladder marker is indicated as M; 50bp DNA Ladder marker is indicated as M".


Female Male

Control for deletion of His3.3B and His3.3A Control for deletion of HisC and presence of Gal4 and H3K36R



Appendix Figure S11. Recombination of *ash1* and *NSD* mutations. The *NSD* loss of function allele, NSD^{ds46} , was recombined with three different *ash1* alleles, namely *ash1*²² (**A**), *ash1*⁹⁰¹¹ (**B**), and *ash1*²¹ (**C**) using identical set of crosses. First, the homozygous NSD^{ds46} fly strain was crossed with the *ash1* mutant strain in which the *ash1* allele was balanced over the *TM3,Ser,Act-GFP* balancer chromosome (Step 1). In Step 2, the males of the *TM6,Tb* balancer chromosome strain were crossed with the female progeny of Step 1 that lacked the *TM3* balancer. The recombination between the NSD^{ds46} and *ash1* alleles occurred in these females. In the NSD^{ds46} deletion, the coding region of *NSD* is replaced with the *DsRed* ORF. Therefore, the female progeny of Step 2 were selected based on the RFP signal and the presence of the

TM6, *Tb* balancer and crossed individually to the $ash1^{9011}/TM3$, *Ser*, *Act-GFP* males (Step 3). After egg deposition, genomic DNA was extracted from the females in each individual cross and screened by PCR for the presence of the relevant ash1 allele (see Appendix Figure S12). The progeny of the crosses with females carrying the recombinant chromosome, balanced over *TM3*, *Ser*, *Act-GFP* balancer was used to establish the strains shown as Step 4. (**D**) Generation of the ash1, *NSD* double mutant animals. The *NSD*^{ds46} allele is homozygous viable, however, the $ash1^{22}$, $ash1^{9011}$, and $ash1^{21}$ chromosomes all carry additional unrelated lethal mutations. Therefore, to obtain the ash1, *NSD* double-mutants, different *NSD*^{ds46}, ash1 fly strains were crossed to each other and the GFP-negative first instar larvae (Class I, double mutants) were separated from the GFP-positive (Class II) larvae and grown separately to avoid competition.



Appendix Figure S12. Genotyping *ash1, NSD*^{*ds46*} **recombinants.** The single flies described in Appendix Figure S11A-C, were genotyped by PCR, using primers specific for *ash1* mutations. The presence of RFP (thus deletion of *NSD*) was checked prior to DNA extraction and only the RFP-positive flies were selected for further screening for the *ash1* mutations. (**A**) The screen for the *ash1*²¹ allele. Forward primer in the $ash1^{21}$ amplicon is designed to match the single nucleotide substitution in the *ash1*²¹ mutation and therefore anneals only to the mutant genomic DNA but not to the wild-type *ash1*. Seven out of ten single flies shown here contain the *ash1*²¹,*NSD*^{*ds46*} recombinant chromosome. (**B**) The screen for the *ash1*²² allele. In this case, one of the primers is specific for the $ash1^{22}$ allele, therefore the PCR product is seen only in the mutant but not in the wild-type flies. Only two single flies positive for $ash1^{22}$ mutation are shown here. (C) The screen for the $ash1^{9011}$ allele. One of the primers (9011-1.2) in the $ash1^{9011}$ amplicon is specific to the genomic DNA flanking the deletion and the other primer is specific to the remnant of the transposon used to generate the deletion. Therefore, the $ash1^{9011}$ amplicon yields the product only from the mutant but not the wild-type DNA. Out of four flies shown here, the two contain the $ash1^{9011}$ deletion. PCR products were analyzed by the electrophoresis in 2% agarose gel. M = 50bp DNA Ladder.

Oligonucleotide sequence 1gRNA_NSD_asen AAACTCGATCTCGGAGTGCGCGTC 1gRNA_NSD_sens CTTCGACGCGCACTCCGAGATCGA 2gRNA_NSD_asen AAACTCAACTACTTGTGGGACGAC 2gRNA_NSD_sens CTTCGTCGTCCCACAAGTAGTTGA 3R-nc-1.1 TTGCGGAGCGTGAGCGGAAG 3R-nc-1.2 AAGCCAGGAGAACGGCACGC 9011-1.2 CAGTGCCTTGGCAGTTGATGTC Abd-B F ex CCACTGCATATACCCGCCAT AATCCCTCGTCGTTGTAGGC Abd-B_R_ex ASH1_mE_Fwd TGGATCCCCGGAATTGCAGCTCTTTGTGGAGGCCAAG ASH1 seq10 AGCCATTGATTACCAAGAGTGCG ASH1_seq11 ATTCGGGTGTGATAAGCACCAC ASH1_seq12 TTTCGTCAGAGGAGGAACCTGG ASH1_seq2 TGCTAAGTGCTATCATCCAGGC ASH1 seq3 CCAGGAGTAAGCGACGGCAG ASH1 seq4 TGATGAACCAGCGTAAAGAAACCC ASH1 seq5 AATGGGAAATTGAACGCAGAGGC ACAACAGCCGTGATTGATGAGC ASH1 seq6 ATTCCTACCGAGCACGATCCC ASH1_seq7 ACTAAGCTACCCATTGCGAAGGG ASH1 seq8 ASH1_seq9 AAAAGATACGCAGATGCAAGGCC ash1-21.mut CAACCGCATGGTTTATACGA ash1-21.rev CTGCTTGAATTCCTTTTCCG ash1-22.2 GTGCAGCGTTCGGACACCGA ash1-22.R CCGACTGTGCCGCCTGGATG ash1-22-rev TCCGAGGAAAATGCCGAGATCTA ASH1CN Cfwd AGATCTCCAAGAGCTATGCGC GTCTAGATATCTCGATTACTCGAGTGTTGAGTTGGCCGTAGAACTG ASH1CN_Crev ASH1CN Nfwd AGTCGACTGGATCCGACCATGGGTACCAGCTGTAGCCAAAATGAGACGG ASH1CN Nrev AGCTCTTGGAGATCTGTGACTTCTTAGACTTAGACAC CP190-ACTTCACCCAGTGCGGCCGCCGATACAGTCAACTGTCTTTGACCTT GAL4:DBD-rev deltaPHD A CAGAAGGCCAAAAAGCATGCTC CCACTTCATCCTCATCAGGAGAGGCCTC deltaPHD B ATGAGGATGAAGTGGATCGAGAAATTCCCC deltaPHD C TGACCAACTCAATGGGTACCAC deltaPHD D ATCCGCACCAATGTATACGCAG deltaSET_A deltaSET_B AGGGATTGACGGCATGTCGCTGGATCTTC deltaSET C ATGCCGTCAATCCCTCAGAGGGTCAGCC

Appendix Table S1. The list of oligonucleotide sequences.

Oligonucleotide	sequence	
deltaSET_D	CCGCCTGCCGTTGAGC	
DonR_forB	CAATAGCATCACAAATTTCACAAATAAAG	
DonR_revA	GATCCTAATTGAATTAGCTCTAATTG	
eGFP_F	CAAGGACGACGGCAACTACA	
eGFP_R	CCTCCTTGAAGTCGATGCC	
emc.1.1	GATCCAGATATCCTCGCCCAGC	
emc.1.2	CCACAAGAGTGTTGGGCGTTTG	
emc-2.1	GAGCGAGTTTTCTCACGCAG	
emc-2.2	GCAGGTCGAGTTTTCAACGG	
gen_1_NSD	TAAACTGGACCGCAGAATGAAG	
gen_16_NSD	GTGTTTCACCTTGGGAGTCTTC	
H3K36R	GCCACCGGAGGTGTGCGC	
H3WT	CAGCCACCGGAGGTGTGAAG	
HA-1-PstI	TACTGCAGTCTTGATAAAGTCGTCCATGCTCCTTG	
HA-1-SpeI	TAACTAGTATCTCGGAGTGCGCGTCCGTGCTCAGC	
HA-2-EcoRI	TA GAATTC TCCGTGCGCAACTGCCTGAAGCTG	
HA-2-NotI	TAGCGGCCGC ACTACTTGTGGGACGACTTAATG	
His3.3A_fwd	TAGGGTCACACTGAGCAGACGC	
His3.3A_rev	TGAATGCATTTACTACATGG	
His3.3B_fwd	TCTGTGTCAATCTGGAACGC	
His3.3B_rev	GAGAAATTCATATGAGTTGGATAACC	
His3-rev	AATGCGTCGCGCTAACTGGATG	
HisC.2	TTACGCCGATAAGACACTAACG	
hth.1.1	TGTGTTTTTGCGACGGCAATTTG	
hth.1.2	GCCGCGGAGGGAATTTCTTTC	
hth-2.1	GACCGCTCCGAAAAGTAGGG	
hth-2.2	AACTCCGGACTCGGACTCTT	
Mes-4-RI-2.1	CTAATACGACTCACTATAGGGAGTTCAGTCCGGCAAAGGTCAGC	
Mes-4-RI-2.2	CTAATACGACTCACTATAGGGAGTACATGAGCCCCATCGAGAAGC	
noc-exp-1.1	AGATTTCCGCGCACGATTCCTC	
noc-exp-1.2	TTCCGTTGGCATTGTTCAGCACC	
NSD_back	TTACTCGTCCTTCGCATCCATTGGCTCA	
NSD-Rt-1f	CCATGGTGAACAGGAAACGAG	
NSD-Rt-1r	CATCTGTCCGGTCAACTTCCTCATC	
OneStrep_fwd	TGGATCCGACCATGGCTAGCTGGAGCCACCCGCAGTTCGAGAAAGGTGG AGGTTCCGGAGGTGGATCGGGAGGTGGATCGTGGAGCCACCCGCAGTTC GAAAAAGGCGC	
OneStrep_rev	TTTTGGCTACAGCTGGCGCCTTTTTCGAACTGCGGGTGGCTCCACGATCCA CCTCCCGATCCACCTCCGGAACCTCCACCTTTCTCGAACTGCGGGTGGCTC CAGGTAC	
osGAL4:DBD-fw	TTCGAAAAAGCGGCCAAGCTACTGTCTTCTATCGAACAAGCAT	
Plac1	CACCCAAGGCTCTGCTCCCACAAT	

Oligonucleotide	sequence
Pry4	CAATCATATCGCTGTCTCACTCA
rp49for	TGTCCTTCCAGCTTCAAGATGACCATC
rp49rev	CTTGGGCTTGCGCCATTTGTG
RpL32-ex1.1	TGGGCGATCTCGCCGCAGTA
RpL32-ex1.2	CAGAGTGCGTCGCCGCTTCA
Su(z)2-2.1	CGTGCCGGTCGAACTGTTAT
Su(z)2-2.2	TCCTTAGCCCGCTTTCTGTT
Su(z)2-ex1.1	GCCAAGGCCCAGAGCTACGC
Su(z)2-ex1.2	GGTGGTCCCATCAAGCGGGC
Taf4-ex1.1	AGCCCGCAGCCGTGTTTGAT
Taf4-ex1.2	CGTGCTGCGGCGGAGGTTTA
Ubi-1.1	GGCGGCCGTTACTAGAAGGATCCTTTAGGCTTTTGCC
Ubi-1.2	TTGATGATCCACTAGTTTGGATTATTCTGCGGGAAGAAA
U-ex1.1	GTCTTTGTAGCCATTCACCG
U-ex1.2	CCCTATGCCAACCACCATC

Appendix Table	S2.	The list	of antibodies.
-----------------------	-----	----------	----------------

Antigen	Host	Reference/company/catalogue #	IF	Western	ChIP
H3K36me1	rabbit monoclonal	Cell Signaling, D9J1D, Cat#14111	-	1:2000	1:250
H3K36me2	mouse monoclonal	Active motif, MABI0332, Cat#61019	-	1:1000	1:100
H3K36me3	rabbit monoclonal	Cell Signaling, D5A7, Cat#4909	1:200	1:2000	-
H3K27me2	rabbit monoclonal	Cell Signaling, Cat#9728S	-	1:2000	-
H3K27me3	rabbit polyclonal	Millipore (Upstate), 07-449	-	1:2000	-
BEAF-32	rabbit polyclonal	#21352 gift from H. Saumweber	-	1:2000	-
H3K18Ac	rabbit polyclonal	Abcam, # ab1191	1:200	-	-
Ash1	rabbit polyclonal	Kahn at al., 2016	-	-	1:100
Ash1	rabbit polyclonal	against aa 2156-2217, gift from V.Pirrotta	-	1:500	-
Abd-B	mouse monoclonal	DHSB, 1A2E9	1:10	-	-
Ubx	mouse monoclonal	DHSB, Ubx FP3.38	1:50	-	-
Anti-rabbit Alexa-488	Goat	Invitrogen, # A-11008	1:500	-	-
anti-mouse Alexa-555	Goat	Abcam, # ab150114	1:500	-	-
Anti-Rabbit AP conjugated	Goat polyclonal	Promega, #S3731	-	1:10000	-
Anti-Mouse IgG AP conjugated	Goat polyclonal	Sigma, A3562	-	1:10000	-
Anti-Elav (68 µg/ml)	mouse monoclonal	DHSB, Elav-9F8A9-s	5 µg/ml	-	-

Amplicon name	Oligo name	ChIP
intergenic	3R-nc-1.1	Ash1, H3K36me1, H3K36me2
	3R-nc-1.2	Asiri, 115K50ille1, 115K50ille2
noc	noc-exp-1.1	Ash1, H3K36me1, H3K36me2
lioc	noc-exp-1.2	
	hth.1.1	Ash1
hth	hth.1.2	
1101	hth-2.1	H3K36me1, H3K36me2
	hth-2.2	
Ubx	U-ex1.1	Ash1, H3K36me1, H3K36me2
00x	U-ex1.2	
	Su(z)2-2.1	Ash1
Su(z)2	Su(z)2-2.2	
5u(2)2	Su(z)2-ex1.1	H3K36me1, H3K36me2
	Su(z)2-ex1.2	
	emc.1.1	Ash1, H3K36me1
emc	emc.1.2	
enic	emc-2.1	H3K36me2
	emc-2.2	
Taf4	Taf4-ex1.1	Ash1, H3K36me1, H3K36me2
1 814	Taf4-ex1.2	

Appendix Table S3. Amplicons used in ChIP-qPCR.